New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 9, 2012
09:02 EDTSGEN, RHHBYSeattle Genetics to receive milestone payments as Genentech advances two ADCs
Seattle Genetics (SGEN) will receive undisclosed milestone payments under its antibody-drug conjugate collaboration with Genentech, a member of the Roche Group (RHHBY). The milestones were triggered by Genentech’s advancement of two ADCs utilizing Seattle Genetics technology into phase II clinical development. The phase II randomized, open-label study is designed to evaluate the safety and efficacy of ADCs anti-CD22 and DCDS4501A each in combination with Rituxan in patients with relapsed or refractory follicular non-Hodgkin lymphoma and relapsed or refractory diffuse large B-cell lymphoma.
News For SGEN;RHHBY From The Last 14 Days
Check below for free stories on SGEN;RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
09:09 EDTRHHBYRoche to hold an investor update
Subscribe for More Information
08:15 EDTRHHBYEnzo Biochem announces August 18 as date of Markman hearing in lawsuit
Subscribe for More Information
05:58 EDTRHHBYExelixis shares rallied on Roche rumors, says Piper Jaffray
Subscribe for More Information
July 28, 2014
07:30 EDTRHHBYQ1 Productions to hold a conference
Subscribe for More Information
July 25, 2014
07:35 EDTRHHBYEMA recommends new indication for RoActemra in severe arthritis
Subscribe for More Information
July 24, 2014
06:13 EDTRHHBYRoche reaffirms outlook for 2014
Subscribe for More Information
06:12 EDTRHHBYRoche reports 1H core EPS CHF 7.57 vs. CHF 7.58 last year
Subscribe for More Information
July 23, 2014
09:08 EDTRHHBYUltragenyx appoints Sunil Agarwal, M.D. as Chief Medical Officer
Subscribe for More Information
July 22, 2014
05:21 EDTRHHBYRoche announces Genentech Avastin granted priority review by FDA
Subscribe for More Information
July 21, 2014
07:11 EDTRHHBYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:43 EDTRHHBYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
15:42 EDTRHHBYRoche not looking for big acquisitions, Reuters says
Subscribe for More Information
July 17, 2014
17:42 EDTRHHBYCepheid says Roche patent suit will not have material adverse impact on results
Subscribe for More Information
July 16, 2014
11:23 EDTRHHBYRoche Alzheimer drug shows mixed results in trial, NYT says
Subscribe for More Information
06:26 EDTRHHBYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
05:37 EDTRHHBYGenentech Avastin granted priority review by FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use